BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 16, 2011
View Archived Issues
StemCells begins phase I/II neural stem cell trial in spinal cord injury
Read More
Tumor-targeted nonclustered nanoparticles effective as MRI probes
Read More
Iron chelator M-30 may be beneficial in amyotrophic lateral sclerosis
Read More
ACADIA Pharmaceuticals presents new muscarinic acetylcholine receptor agonists
Read More
Start-up biotech company ImmusanT focuses on celiac disease immunotherapy
Read More
Novel HIV integrase inhibitors patented by Merck & Co.
Read More
Biodel selects two ultrarapid-acting insulin formulations for clinical development
Read More
Novel series of protein kinase inhibitors presented by Merck & Co.
Read More
Novel tyrosine-protein kinase BTK inhibitors presented by Bristol-Myers Squibb
Read More
University of Virginia presents new sphingosine kinase inhibitors
Read More
Anavex Life Sciences cleared to conduct phase I ANAVEX 2-73 study in Germany
Read More
Seattle Genetics and Millennium extend antibody-drug conjugate agreement
Read More
Safety and tolerability of GT-MAb 2.5-GEX seen in phase I trial in advanced/metastatic cancer
Read More
Daiichi Sankyo postpones Japanese launch of Memary tablets for Alzheimer's due to earthquake
Read More
Unigene begins dosing in phase II study of oral parathyroid hormone for osteoporosis
Read More
Boehringer Ingelheim obtains rights to Acuform technology and Glumetza data
Read More
Pluristem Therapeutics and NYU Medical Center partner to treat diabetic foot ulcers
Read More
Researchers describe protein aggregation inhibitor with potential for neurodegenerative diseases
Read More
Vernalis begins dosing patients in phase I trial of pain candidate V-158866
Read More
Cleveland Clinic grants Apeiron option to license SHP-1 inhibitors
Read More
Chinese health authorities approve Novo Nordisk's Victoza for type 2 diabetes
Read More
Agennix completes enrollment of phase III FORTIS-M trial of talactoferrin in NSCLC
Read More
In vivo protective effects of carbon nanotubes against ischemic brain injury
Read More
Src disruption enhances sensitivity of multiple myeloma cells to Chk1 inhibitors
Read More